ALFA Finder| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 9% YoY growth to ₹82 Cr, organic growth accelerating. |
|---|---|
| Margins | EBITDA margins expanded by 240 bps to 23% plus. |
| Demand visibility | Strong visibility in Gynaecology, Ortho, and Dermatology segments. |
| Management confidence | High confidence in 1.5x industry growth rate targets. |
Growth
Revenue grew 9% YoY to ₹82 Cr, while EBITDA and Net Profit grew 21% and 22% respectively.
Outlook
Equitas is expected to hit ₹100 Cr revenue and ₹10 Cr EBITDA by Year 2 post-integration.
Risks
High concentration in the 'Maintain' brand and historically longer working capital cycles in the hospital segment.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (MAT 12.2%) (= BEAT)
- Guided 1.5x IPM growth → delivered 14.2% vs 10.5% industry (= BEAT)
- Guided 19% PAT growth → delivered 19% profit growth (= BEAT)
Earnings Call Transcript filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹216.15
- Market cap
- ₹1,426 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 31.3×Sector 43.7×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited